NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Allen Biotechnology Co ABC

Published 12 Nov 2026. 34-page investigative report on who is behind Allen Biotechnology Co ABC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 76 Finnrick lab tests, Allen Biotechnology Co ABC records 55 pass / 21 fail, for a 72% overall pass rate. The useful buyer signal is dispersion, not a single vendor-wide verdict. Retatrutide is the strongest Allen line in the current record, while tirzepatide combines a large mixed test history with identity and fill concerns. BPC-157 and TB-500 sit in the avoid-or-test-first tier, and Allen's ratings move materially under stricter fill and purity grading.

The company surface has changed quickly. Allen now appears as a forum-and-Telegram seller wrapped in a newer storefront network, with related Allen, Welon and LiliPeptide sites sharing template features and ABT Labs LLC footer language. That operator claim is visible on the sites, but the report does not verify it through a public registry record. A dissolved UK namesake exists, but the filing trail does not connect it to the current channels.

The polished biotech layer raises a different problem: not lack of biography, but unverified assurance. The site claims patents, active programs, collaborators and named executives; patent, trial and public professional-profile checks did not corroborate those credibility signals in the reviewed sources. Allen also publishes a COA archive, but its current order guide states lower purity/content standards and says a public Janoshik report may not be available for a lot. Crypto-only payment rails, a prior postage/tracking crisis and cloaked search pages targeting Allen keywords add practical recourse and authenticity risk.

Inside the full report:

  • Appendix A lab data, rating trajectories and methodology-divergence charts for all 6 tracked products
  • RDAP domain timeline and storefront-template comparison for Allen, Welon and LiliPeptide
  • ABT Labs LLC ownership trail, UK namesake filing analysis and blocked-registry limitations
  • COA archive review versus the Google order guide, including Janoshik access limits and release-control gaps
  • GLP-1 Forum, Telegram, shipping, pricing and crypto-payment recourse trail
  • Search-cloak and brand-confusion evidence from institutional-domain redirects

Risk assessment

  • Tirzepatide quality and identity risk — high: 40 Finnrick tests, 30 pass / 10 fail, 74.37%; prior severe fill deviations and an identity failure on a 60mg-labeled sample, batch 60-T-7-5.
  • BPC-157 quality risk — high: 5 Finnrick tests, 0 pass / 5 fail, 40.36%; avoid or independently test every vial.
  • TB-500 quality risk — high: 4 Finnrick tests, 1 pass / 3 fail, 35.8%; fail-heavy at a small sample.
  • Tesamorelin purity/variability risk — medium: 9 Finnrick tests, 7 pass / 2 fail, 59.15%; documented severe purity outlier.
  • PT-141 evidence-quality risk — medium: 4 Finnrick tests, 3 pass / 1 fail, 67.53%; thin evidence base for a buyer relying on this SKU.
  • Operational/logistics integrity risk — high: Sept.–Oct. 2025 USPS/postage/tracking crisis and partial refunds; Feb. 2026 CNY no-response complaint shows channel-latency risk.
  • Corporate-transparency and identity risk — high: ABT Labs LLC operator claim unverified; four July–Oct. 2026 storefronts, conflicting governing law, and unfinished terms weaken accountability.
  • Payment/recourse risk — high: Crypto/stablecoin only, USDT, USDC, PYUSD, BTC, ETH and SOL; no chargeback path documented.
  • Storefront-claim accuracy risk — high: Storefronts claim 99%+ and every-batch verification, while order guide states ≥98% purity, ≥90% content, and Janoshik reports may be unavailable.
  • Brand-confusion and authenticity-verification risk — medium: Cloaked .edu/.org search pages redirect Allen-keyword traffic to unrelated WhatsApp groups; vendor provides no single canonical domain or authorized-channel list.